Testing the neurovascular hypothesis of alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-β protein, and impairs cognition

Journal of Alzheimer's Disease

Volumn 17, Issue 3, 2009, Pages 553-570

  Jaeger, Laura B ^a,b   Dohgu, Shinya ^a,b   Hwang, Mark C ^a,b   Farr, Susan A ^a,b   Murphy, M Paul ^c   Fleegal Demotta, Melissa A ^a,b   Lynch, Jessica L ^a,b   Robinson, Sandra M ^a,b   Niehoff, Michael L ^a,b   Johnson, Steven N ^a,b   Kumar, Vijaya B ^a,b   Banks, William A ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; Antisense; Blood brain barrier; Cognition; Learning; Low density lipoprotein receptor related protein 1 (LRP 1); Memory; Transporter

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN[1-42]; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MESSENGER RNA; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PREPROENKEPHALIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG PENETRATION; DRUG UPTAKE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MALE; MAZE TEST; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN FIELD TEST; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECOGNITION; TISSUE LEVEL; WESTERN BLOTTING;

EID: 67849099661     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-1074     Document Type: Article

References (46)

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60, 1119-1122.
2. Selkoe DJ (1998) The cell biology of the β3-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 8, 447-453.
3. Selkoe DJ (1994) Normal and abnormal biology of the β3- amyloid precursor protein. Rev Neurosci 17, 489-517.
4. Gravina SA, Ho L, Eckman CB, Long KE, Otvos L Jr., Younkin LH, Suzuki N, Younkin SG (1995) Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 270, 7013-7016.
5. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of Abeta 42(43) and Abeta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13,45-53.
6. Jaeger LB, Banks WA (2004) Antisense therapeutics and the treatment of CNS disease. Front Biosci 9, 1720-1727.
7. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad SciUSA 82, 4245-4249.
8. Hock BJ Jr., Lamb BT (2001) Transgenic mouse models of Alzheimer's disease. Trends Genet 17, S7-S12.
9. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB (2003) Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 278, 2081-2084.
10. Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28, 202-208.
11. Deane R, Sagare A, Zlokovic B (2008) The role of the cell surface LRP and soluble LRP in blood-brain barrier Aβ clearance in Alzheimer's disease. Curr Pharm Design 14, 1601-1605.
12. Zlokovic BV (1996) Cerebrovascular transport ofAlzheimer's amyloid beta and apolipoproteins J and E: possible anti- amyloidogenic role of the blood-brain barrier. Life Sci 59, 1483-1497.
13. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Fran-gione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J,Zlokovic BV (2000) Clearance of Alzheimer's amyloid-β 140 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106, 1489-1499.
14. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katz- man R, Koo EH (1998) Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LRL receptor-related protein pathway. J Clin Invest 106, 1159-1166.
15. WillnowT, Armstrong S, HammerR, Herz J (1995) Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. Proc Natl Acad Sci USA 92, 4537-4541.
16. Banks WA, Robinson SM, Verma S, Morley JE (2003) Efflux of human and mouse amyloid beta proteins 1-40 and 1-42 from brain: impairment in a mouse model of Alzheimer's disease. Neuroscience 121, 487-492.
17. Jaeger LB, Banks WA (2005) Transport of antisense across the blood-brain barrier. In Methods Mol Med: Antisense Therapeutics (Phillips MI, ed), pp. 237-251. Humana Press Inc., New Jersey.
18. Banks WA, Farr SA, Butt, W, Kumar VB, Franko MW, Morley JE (2001) Delivery across the blood-brain barrier of antisense directed against amyloid β reversal of learning and memory deficits in mice over expressing amyloid precursor protein. J Pharmacol Exp Ther 297, 1113-1121.
19. Dogrukol-Ak D, Kumar VB, Ryerse JS, Farr SA, Verma S, Nonaka K, Nakamachi T, Ohtaki H, Niehoff ML, Edwards JC, Shioda S, Morley JE, Banks WA (2009) Isolation of peptide transport system-6 from brain endothelial cells: therapeutic effects with antisense inhibition in Alzheimer's and stroke models. J Cereb Blood Flow Metab 29, 411-422.
20. Banks WA, Jaeger LB, Urayama A, Kumar VB, Hileman SM, Gaskin FS, Llanza NV, Farr SA, Morley JE (2006) Preproenkephalin targeted antisenses cross the blood-brain barrier to reduce brain methionine enkephalin levels and increase voluntary ethanol drinking. Peptides 27, 784-796.
21. Mare S, Penugonda S, Robinson SM, Dohgu S, Banks WA, Er- cal N (2004) Copper complexing decreases the ability ofamy- loid beta peptide to cross the BBB and enter brain parenchyma. Peptides 43, 333-344.
22. Szabó CA, Deli MA, Ngo TKD, Joó F (1997) Production of pure primary rat cerebral endothelial cell culture: a comparison of different methods. Neurobiology 5, 1-16.
23. Perrière N, Demeuse P, Garcia E, Regina A, Debray M, Andreux JP, Couvreur P, Scherrmann JM, Temsamani J, Couraud PO, Deli MA, Roux F (2005) Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. J Neu-rochem 93, 279-289.
24. Dehouck MP, Jolliet-Riant P, Brée F, Fruchart JC, Cecchelli R, Tillement JP (1992) Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. J Neurochem 58, 1790-1797.
25. Gerhart DZ, Broderius MA, Drewes LR (1998) Cultured human and canine endothelial cells from brain microvessels. Brain Res Bull 21, 785-793.
26. Blasberg RG, Fenstermacher JD, Patlak CS (1983) Transport of alpha-aminoisobutyric acid across brain capillary and cellular membranes. JCereb Blood Flow Metab 3, 8-32.
27. Morley JE, Farr SA, Flood JF (2002) Antibody to amyloid beta protein alleviates impaired acquisition, retention, and memory processing in SAMP8 mice. Neurobiol Learn Mem 78, 125-138.
28. Banks WA, Coon AB, Robinson SM, Moinuddin A, Shultz JM, Nakaoke R, Morley JE (2004) Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 53, 1253-1260.
29. Triguero D, Buciak J, Pardridge WM (1990) Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem 54,1882-1888.
30. Gutierrez EG, Banks WA, Kastin AJ (1993) Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J Neuroimmunol 47, 169-176.
31. Jaeger LB, Banks WA, Varga JL, Schally AV (2005) Antagonists of growth hormone-releasing hormone cross the blood- brain barrier: A potential applicability to treatment of brain tumors. Proc Natl Acad Sci USA 102, 12495-12500.
32. Slotnick BM, Leonard CM (1975) A stereotaxic atlas of the albino mouse forebrain. U.S. Department ofHealth, Washington DC.
33. Ramsden M, Nyborg AC, Murphy MP, Chang L, Stanczyk FZ, Golde TE, Pike CJ (2003) Androgens modulate beta-amyloid levels in male rat brain. J Neurochem 87, 1052-1055.
34. Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE (2003) Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-β- knock-out mice.J Neurosci 23, 8532-8538.
35. Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, MeritS, Ozols VV, Anastasiadis PZ, Das P, Fauq A, Koo EH, Golde TE (2005) Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 11,545-550.
36. Diano S, Farr SA, Benoit SC, McNay EC, da Silva I, Horvath B, Gaskin FS, Nonaka N, Jaeger LB, Banks WA, Morley JE, Pinto S, Sherwin RS, Xu L, Yamada KA, Sleeman MW, Tschop M, Horvath TL (2006) Ghrelin controls hippocampal spine synapse density and memory performance. Nat Neurosci 9, 381-388.
37. Jaeger LB, Farr SA, Banks WA, Morley JE (2002) Effects of orexin-A on memory processing. Peptides 23, 1683-1688.
38. Joo F (1993) The blood-brain barrier in vitro: the second decade. Neurochem Int 23, 499-521.
39. Bu G, Maksymovitch EA, Gueze H, Schwartz AL (1994) Subcellular localization and endocytic function oflow density lipoprotein receptor-related protein in human glioblastoma cells. JBiol Chem 47, 29874-29882.
40. Deane R, Yan SD, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J,Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 7, 907-913.
41. Maness LM, Banks WA, Podlisny MB, Selkoe DJ, Kastin AJ (1994) Passage of human amyloid β protein 1-40 across the murine blood-brain barrier. Life Sci 21, 1643-1650.
42. Pan W, Solomon B, Maness LM, Kastin AJ (2002) Antibodies to 6-amyloid decrease the blood-to-brain transfer of β-amyloid peptide. Exp Biol Med 227, 609-615.
43. Ghersi-Egea JF, Gorevic PD, Ghiso J, Frangione B, Patlak CS, Fenstermacher JD (1996) Fate of cerebrospinal fluid-borne amyloid βpeptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem 67, 880-883.
44. Giri R, Shen Y, Stins M, Du Yan S, Schmidt AM, Stern D, Kim KS, Zlokovic B, Kalra VK (2000) Beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiology 279, C1772- C1781.
45. Poon HF, Farr SA, Banks WA, Pierce WM, Klein JB, Mor- ley JE, Butterfield DA (2005) Proteomic identification of less oxidized brain proteins in aged senescence-accelerated mice following administration ofantisense oligonucleotide directed at the Abeta region of amyloid precursor protein. Mol Brain Res 138, 8-13.
46. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lent- ing PJ, Van Nostrand WE, Zlokovic BV (2004) LRPβamyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333-344.